Avista Capital Partners-backed Arcadia Consumer Healthcare has acquired Naturelo, expanding into the fast-growing universe of nutritional supplements, PE Hub has learned.
For Arcadia, formerly known as Kramer Laboratories, the acquisition diversifies the company beyond the traditional over-the-counter medicines in which it has historically focused. Some of its best known brands include Nizoral, Kaopectate, Fungi-Nail and Opti-Nail.
Naturelo, founded in 2013, is a premium vitamins, minerals and supplements brand that serves customers across 93 countries.
Its portfolio of natural products includes prenatal & postnatal multivitamins as well as health lines for men, women and children, specialty supplements, green superfood powder, vitamins, minerals, omegas and probiotics.
For the Bridgewater, New Jersey, platform company, Naturelo is its second buy this year. Arcadia in March bought the US rights to the Kaopectate brand from Sanofi.
Healthcare investor Avista, of New York, and Dana Holdings, a consumer healthcare-focused private investment group, purchased Arcadia in May 2018. Avista’s investment in Arcadia is led by partner Rob Girardi. The firm invested out of Fund IV, for both the initial platform and Arcadia.
Avista’s fourth vehicle closed in 2017, collecting more than $800 million, PE Hub previously wrote. The firm had raised more than $600 million for its fifth flagship as of April, an SEC filing showed.
Founded in 2005 as a spinout from DLJ Merchant Banking, Avista has been an active dealmaker through the pandemic.
In September, Avista’s National Spine & Pain Centers joined forces with Prospira PainCare, a portfolio company of Enhanced Healthcare Partners and Webster Equity Partners, PE Hub reported. The marriage of the pain-management platforms left Avista with the largest ownership stake, sources said at that time.
In June, Avista agreed to buy a 50 percent stake in Belgium’s Vision Healthcare NV, investing alongside VHC Investco and company management. The deal valued Vision Healthcare, which owns and markets a branded portfolio of self-care and over-the-counter products, at $336 million, inclusive of contingent payments.
Action Item: Check out Avista’s latest Form ADV.